The global Immunoassay testing Market is projected to grow from USD 35.5 billion in 2025 to USD 47.7 billion by 2030, registering a CAGR of 6.1% during the forecast period. Market expansion is being driven by the growing burden of chronic and infectious diseases, an aging global population, increasing demand for early disease detection, and continued adoption of automated and high-throughput diagnostic technologies.
Download PDF Brochure:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=436
Rising Chronic Disease Burden Fuels Immunoassay Adoption
The increasing prevalence of cancer, diabetes, cardiovascular diseases, infectious diseases, and other chronic and age-related conditions is generating sustained demand for accurate and efficient diagnostic testing.
Immunoassays play a critical role in detecting and monitoring a broad range of biomarkers, hormones, antibodies, antigens, and other disease-related indicators. The growing global elderly population is further increasing the need for routine screening, early diagnosis, and disease monitoring.
In addition, emerging markets are creating new opportunities for immunoassay manufacturers as healthcare infrastructure expands and governments, laboratories, and healthcare providers increase investments in diagnostic capabilities and R&D.
Reagents & Kits Segment Held the Largest Market Share
The reagents & kits segment accounted for the largest share of the Immunoassay testing Market, by product, in 2024.
The dominance of this segment is primarily attributed to the recurring consumption of reagents and kits across diagnostic workflows. Unlike analyzers, which represent longer-term capital investments, reagents and kits are consumed during individual tests, generating recurring demand from clinical laboratories, hospitals, research institutions, and decentralized testing facilities.
The increasing volume of immunoassay testing across infectious diseases, endocrinology, oncology, and other diagnostic applications is expected to continue supporting demand for high-quality reagents and assay kits.
Growing adoption of automated and high-throughput testing platforms is also creating opportunities for manufacturers to develop compatible and application-specific consumables.
ELISA Maintains Leadership Among Immunoassay Technologies
ELISA accounted for the largest share of the immunoassay technology market in 2024.
ELISA remains widely adopted because of its versatility, established clinical applications, cost-effectiveness, and ability to deliver sensitive and specific diagnostic results.
The technology is extensively used across infectious disease testing, cancer screening, immunology, and other clinical and research applications.
Its compatibility with laboratory automation and high-throughput workflows further strengthens its position among clinical laboratories. Continued improvements in assay design, automation, and digital result interpretation are expected to enhance workflow efficiency and support sustained demand for ELISA-based testing solutions.
Hospitals & Clinics Represent the Largest End-User Segment
Hospitals & clinics accounted for the largest share of the Immunoassay testing Market by end user in 2024.
Hospitals and clinics perform large volumes of diagnostic testing across emergency care, outpatient services, specialized departments, and inpatient settings.
The increasing adoption of automated, multiplexed, and high-throughput immunoassay platforms is enabling healthcare providers to improve turnaround times and diagnostic efficiency while managing growing patient volumes.
The integration of immunoassay systems into broader laboratory automation and healthcare information technology environments is also supporting demand for advanced diagnostic solutions.
North America Leads the Global Immunoassay testing Market
North America accounted for the largest regional share of the Immunoassay testing Market in 2024.
The region’s leadership is supported by advanced healthcare infrastructure, high diagnostic testing volumes, strong R&D capabilities, and the presence of major global diagnostic technology companies.
The US represents a major contributor to regional market growth, supported by increasing demand for sophisticated laboratory diagnostics, automated immunoassay platforms, and point-of-care testing technologies.
Regulatory initiatives, quality-control programs, and collaboration between government agencies and research organizations are also contributing to improved assay standardization, validation, and testing reliability.
Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=436
Emerging Markets Offer Significant Growth Opportunities
Emerging markets are expected to provide attractive opportunities for immunoassay manufacturers and diagnostic technology providers.
Increasing healthcare expenditure, improving laboratory infrastructure, rising awareness of preventive healthcare, and growing investments in diagnostic R&D are expanding access to advanced testing technologies.
As healthcare systems in developing economies transition toward early diagnosis, preventive screening, and data-driven disease management, demand for immunoassay-based diagnostic solutions is expected to increase.
Competitive Landscape
The global Immunoassay testing Market features established diagnostic and life sciences companies competing through new product development, automation, assay innovation, strategic partnerships, geographic expansion, and integrated diagnostic solutions.
Key players profiled in the report include Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Danaher, Revvity, Becton, Dickinson and Company (BD), DiaSorin S.p.A., and Bio-Rad Laboratories, Inc.
These companies are focusing on expanding assay portfolios, strengthening analyzer capabilities, improving automation, and developing solutions for increasingly diverse clinical and research applications.
